Diabetes Mellitus and Risk of Hepatocellular Carcinoma

Xu Li,1 Xiaocong Wang,2 and Pujun Gao1

1Department of Hepatology, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun 130021, China
2Department of Echocardiography, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun 130021, China

Correspondence should be addressed to Pujun Gao; gpj0411@163.com

Received 25 September 2017; Accepted 22 November 2017; Published 12 December 2017

Academic Editor: Naohiko Masaki

Copyright © 2017 Xu Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The occurrence of hepatocellular carcinoma (HCC) is two to three times higher in patients with diabetes mellitus (DM), the prevalence of which is increasing sharply worldwide. The purpose of this review was to describe clinical links between DM and HCC and potential biological mechanisms that may account for this association. We evaluated the role of potential pathways that could account for the development of HCC with different etiologies in the presence of DM. In addition, we also briefly discuss the potential effect of other factors such as type and dosage of antidiabetic medicines and duration of DM on HCC risk.

1. Introduction

Diabetes mellitus (DM), a metabolic disorder characterized by dysregulation of blood sugar and insulin [1–3], has an estimated global prevalence of approximately 9% and is expected to affect 300–400 million worldwide by 2030 [4–10]. In 1986, Lawson et al. reported a relationship between DM and hepatocellular carcinoma (HCC), which is the sixth most common cancer worldwide and accounts for 11% of cancer-related deaths [11]. Multiple observational studies from Europe, Asia, and North America and subsequent meta-analyses support the idea that DM and insulin resistance are independent risk factors for HCC [12–14]. The development of HCC is thought to be related to the proliferative effects of insulin and insulin-like growth factor 1, oncogenic effects of hyperglycemia, and inflammatory effects of obesity [15]. This relationship between DM and HCC is significant even after adjusting for detection bias and reverse causality [16]. In addition, the type and dosage of antidiabetic medication used [17] appear to affect the risk of HCC.

In this clinical review, we present the epidemiological evidence linking DM and HCC, discuss potential molecular mechanisms underlying the development of HCC with different etiologies in patients with DM, and describe the effects of antidiabetic medications and duration of DM on HCC risk.

2. Epidemiological Studies Linking DM and HCC

When DM was first investigated as a risk factor in cancer-related deaths, the causes of these two diseases were unknown [18]. In 1934, a study of 10,000 diabetic patients reported an association between pancreatic cancer and DM [19]. In 1991, a large population-based cohort study conducted by Adami et al. in Sweden (n = 51,008) reported an increased risk of both pancreatic cancer and HCC in patients with DM (relative ratio, approximately 1.5) [20]. Subsequently, the association between DM and HCC has been observed in numerous cohort studies [21–24] and case-control studies [12–14, 25]. In 2006, a meta-analysis of 13 cohort studies and 13 case-control studies conducted by El-Serag et al. found that DM is associated with an approximately 2.5-fold increased risk of HCC [26]. In 2014, Tanaka et al. systematically reviewed epidemiologic investigations on DM and HCC among Japanese populations, 9 of the 10 relative risk (RR) estimates in the case-control studies and 17 of the 24 RR estimates in the cohort studies showed a weak to strong positive association between DM and HCC risk, indicating that the overall evidence in Japan strongly supports an increased risk of HCC among DM patients [27]. Other studies also reported a 2- to 3-fold increased risk of HCC in patients with DM [28], and this association was generally observed in patients free of viral hepatitis [13, 24, 29]. However, several
studies conducted in Taiwan did not find an increased risk of HCC in patients with DM. In 2013, Chen et al. conducted a retrospective cohort study to explore risk factors for HCC in 56,231 adults and reported that DM, metabolic syndrome, and obesity were not risk factors for HCC, regardless of hepatitis B virus (HBV) or hepatitis C virus (HCV) status [30]. Likewise, a case-control study conducted by Lu et al. did not find an association between DM and HCC [31]. In a series of 823 HCC patients and 3459 controls, El-Serag et al. found that DM increased the risk of HCC only in the presence of other risk factors such as HBV, HCV, or alcoholic cirrhosis [32].

3. Biological Mechanisms Linking DM and HCC

The complex process of carcinogenesis can be divided into the following stages: initiation, promotion, and progression. Factors associated with the development of cancer may affect one or more stages. Although the precise biological mechanisms underlying the link between DM and HCC are not completely understood, the following factors may be involved in the neoplastic process: endogenous hyperinsulinemia (insulin resistance), exogenous hyperinsulinemia (treatment with insulin or secretagogues), hyperglycemia, and/or chronic inflammation.

3.1. Hyperinsulinemia, Insulin Resistance, and HCC. Elevated insulin levels caused by insulin resistance in fat, liver, and muscle tissue may explain, at least in part, the increased risk of HCC in DM patients [33]. Hyperinsulinemia can increase insulin-like growth factor 1 (IGF-1), which in turn can stimulate liver cell proliferation [34–41]. In addition, hyperinsulinemia could increase the secretion of matrix proteins and other precursors of hepatic fibrosis by hepatic stellate cells [42] and decrease mitochondrial β-oxidation of fatty acids [43], which is associated with hepatic cellular injury, inflammation, and hepatic fibrosis. Furthermore, insulin resistance is independently associated with the progression of liver fibrosis, which is a risk factor for HCC.

3.2. Obesity, Hyperglycemia, and HCC. Obesity appears to be another factor linking DM and HCC. Type 2 diabetes mellitus (T2DM) is associated with central obesity, which promotes carcinogenesis through the secretion of proinflammatory cytokines by visceral adipose tissue [18]. Obesity is often associated with liver cirrhosis and liver fibrosis progression [44], a primary risk factor for HCC [45].

Hyperglycemia might also have carcinogenic potential [46] through the increased glycosylation of hemoglobin. Glycosylated hemoglobin releases iron, which is a powerful prooxidant that produces free radicals, thereby causing oxidative stress [36, 47]. The high serum iron levels associated with DM may also reflect increased body iron stores [36]. Thus oxidative stress may play a role in pathogenesis of DM and its complications, such as cirrhosis, which is a primary risk factor for HCC.

3.3. Synergistic Interactions between DM and Other HCC Risk Factors. Several studies have described synergistic interactions between DM and other HCC risk factors, such as viral hepatitis and heavy alcohol consumption [13, 48, 49]. Chen et al. investigated the relationship between DM and HBV/HCV infections in a cohort of 23,820 residents of Taiwan, who were followed for 14 years. The results showed that the combination of obesity and DM increased the risk of HCC more than 100-fold in HBV or HCV carriers [24]. Hassan et al. evaluated risk factors for HCC in a case-control study that included 115 HCC patients and 230 controls. The increased risk associated with the combination of heavy alcohol consumption and DM (odds ratio [OR], 9.9; 95% confidence interval [CI], 2.5–39.3) was higher than the risk associated with each risk factor alone [48]. These findings suggest that synergistic interactions between DM and other risk factors for HCC may play a role in hepatocarcinogenesis.

3.4. Inflammatory Cytokines, Epigenetic Mechanisms, and HCC. Chronic inflammation associated with DM may promote the development of HCC through the action of proinflammatory cytokines [50]. Several studies have observed elevated levels of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in obese individuals with DM [51–55]. These cytokines regulate the apoptotic regulators Bcl-2 and Bax, suggesting their potential as apoptotic and inflammatory markers for HCC [56–59].

Epigenetic modifications (DNA methylation, histone modification, and RNA interference) can activate proinflammatory genes that encode nuclear factor kappa B (NF-κB) and proteins involved in JAK/STAT signaling, leading to the deregulation of metabolic pathways and hepatocellular transformation. Numerous epigenetic events and methylated genes have been detected in patient tissues or serum prior to or concurrent with a cancer diagnosis, suggesting their potential use as effective biomarkers for early detection [60–62].

4. Relationship between DM and HCC with Different Etiologies

Several studies have attempted to elucidate the relationship between DM and HCC with different etiologies. A retrospective analysis of patients in the US Department of Veterans Affairs database found that the risk of primary liver cancer was increased by DM only in patients with other risk factors such as HBV, HCV, or alcoholic cirrhosis [32]. However, subsequent studies reported the risk of HCC was increased with DM independent of alcoholic liver disease and viral hepatitis [63, 64]. We therefore reviewed studies exploring the relationships between DM and HCC with different etiologies [32, 65, 66].

4.1. Hepatitis C Virus. DM is closely associated with chronic HCV infection, which contributes to 25% of HCC cases globally [67]. Epidemiological studies have shown that DM is associated with a 2- to 3-fold increase in HCC risk in patients with chronic HCV infection, regardless of whether the patient has undergone curative hepatectomy or antiviral
positive participants found that high HBV load was inversely associated with extreme and central obesity in HBeAg-seropositive patients (adjusted OR, 0.17 and 0.44, resp.; 95% CI, 0.05–0.63 and 0.25–0.78, resp.) [89]. However, HBV load was not associated with liver steatosis in HBeAg-seropositive or HBeAg-seronegative patients (adjusted OR, 1.46 and 0.88, resp.; 95% CI, 0.90–2.36 and 0.72–1.08, resp.). These findings suggest that obesity may cause liver damage via oxidative stress and hepatic steatosis independently of HBV infection.

4.3. Nonalcoholic Fatty Liver Disease. Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis, nonalcoholic steatohepatitis (NASH) characterized by inflammation, and NASH-related fibrosis leading to cirrhosis. NAFLD is now the leading cause of chronic liver disease (including cryptogenic cirrhosis) in both developed and developing countries with rising obesity rates [45, 89–92]. NASH has been shown to lead to cryptogenic HCC [93–95], and HCC tumors related to NAFLD tend to be larger and more advanced when detected compared with those related to hepatitis virus infection [96, 97].

Although DM is involved in the development of HCC in NAFLD [98], it is difficult to study causality because the risk factor (DM) is affected by and interacts with the outcomes (NAFLD and HCC) [99]. Numerous case reports and case reviews indicate DM appears to be a risk factor for NASH, which is a cause of cryptogenic HCC [50], and DM is an independent risk factor for HCC in patients with NASH [100–103]. In addition, obesity and DM are associated with liver fibrosis severity in patients with NASH [45].

4.4. Alcohol. Alcohol abuse is a common cause of HCC, especially in western countries. A study by Kikuchi et al. of 1,478 alcoholic liver cirrhosis patients identified DM as a risk factor for HCC in this patient population [104]. Similarly, a cohort study conducted by Raff et al. found that DM increased the risk for cirrhosis and HCC in patients with alcoholic liver disease [105].

Alcoholic liver disease and NAFLD have similar pathogenetic mechanisms and histological findings but different phenotypes and risk factors [106], with a histological spectrum that ranges from simple steatosis to steatohepatitis, fibrosis, cirrhosis, or HCC. DM, which is a risk factor for NAFLD, may also exacerbate alcoholic liver disease [107] and promote alcohol-related HCC. In fact, a synergistic interaction between alcohol consumption and DM has been observed [13, 48], and alcohol-induced oxidative stress in patients with DM may promote cirrhosis, DNA damage, and ultimately HCC [108, 109].

5. Antidiabetic Medication and Risk of HCC

Results of in vitro and in vivo preclinical studies have suggested that antidiabetic drugs influence the development of multiple cancers. Epidemiological evidence indicates that metformin and thiazolidinediones (TZDs) are associated with a lower overall cancer incidence [17, 110–113]. However, insulin and insulin secretagogues are associated with higher cancer incidence and cancer-related mortality [40, 114]. In
this section, we reviewed the effect of conventional antidiabetic drugs on the risk of HCC in patients with DM.

5.1. Metformin. The metformin is a first-line therapy for T2DM and is often prescribed for prediabetes and DM that is less severe or of shorter duration. Metformin can decrease blood glucose and insulin levels in these patients; however, the mechanism underlying this effect is not entirely clear [115]. In addition, results of several pharmacoepidemiologic studies suggest that metformin use lowers the incidence of cancers, including HCC, in patients with DM [17, 113], whose risk of developing HCC is at least 2-3 times higher than individuals without DM [14]. Long-term metformin treatment appears to inhibit hepatocellular transformation, decreasing the risk of HCC to levels similar to that of nondiabetic patients [116–122]. In a rat model of HCC, DePeralta et al. found that HCC incidence was decreased by 44% when metformin treatment was initiated at the first signs of fibrosis but was unchanged when metformin was not initiated until the first signs of cirrhosis [123]. A nationwide case-control study conducted by Chen et al. [120] found that metformin decreases the risk of HCC in patients with DM by 7% with each additional year of use. However, a cohort study conducted in the UK did not find a lower incidence of HCC in patients receiving metformin compared with those receiving sulfonylurea [124]. Furthermore, a meta-analysis of randomized controlled trials comparing the risk of cancer in patients receiving metformin or other antidiabetic drugs did not observe a protective effect of metformin against HCC [125].

The molecular mechanism underlying the antitumor activity of metformin is unclear. Results of studies in breast cancer cells suggest that metformin inhibits cancer by activating AMP-activated protein kinase (AMPK), which may lead to growth inhibition, thereby decreasing protein synthesis [126]. Other studies indicate that metformin inhibits tumorigenesis through both insulin-dependent and insulin-independent mechanisms [127] and that its effects may be lower in patients with lower insulin levels. In insulin-resistant ob/ob mice, metformin improves fatty liver disease, possibly by attenuating hepatic expression of TNF-α, which promotes insulin resistance and plays a role in hepatocarcinogenesis [128]. Results of several small-scale trials demonstrate the potential for metformin to improve liver histology and body weight in patients with NAFLD [129–131], suggesting another potential pathway by which metformin may prevent HCC. However, a more recent study did not observe a significant improvement in liver histology in NAFLD patients receiving metformin [132]; thus further research evaluating liver histology in patients receiving metformin is needed.

5.2. Thiazolidinediones. Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor gamma (PPARγ) agonists that lower insulin resistance without directly affecting insulin secretion. Pioglitazone and rosiglitazone are the two TZDs currently available in the China.

Although the risk of HCC in patients using TZDs is unclear [133], results of several studies indicate that TZDs may exert a beneficial effect [112, 134–138]. A case-control study by Chang et al. evaluated the effect of TZDs on the risk of liver cancer by identifying 10,741 patients with both DM and liver cancer and 70,559 patients with DM only in the Taiwan National Health Insurance claims database. Their results indicated that both pioglitazone and rosiglitazone significantly decreased the risk of liver cancer [112], with greater benefits associated with higher cumulative dosage [112]. Using the same database, Chen et al. [120] showed that each additional year of TZDs use decreased the risk of HCC in diabetic patients by 9%. In contrast, a nested case-control study using healthcare utilization databases in Italy did not detect a significant effect of TZDs on the risk of HCC [122]. Similarly, a meta-analysis of four observational studies did not find a significant decrease in the risk of HCC in patients with DM who received TZDs (adjusted OR, 0.5; 95% CI, 0.28–1.02) [120, 134, 139, 140].

Anticancer activities of TZDs observed in vitro include growth inhibition and promotion of apoptosis and cell differentiation [141, 142]; thus PPARγ has been identified as a potential therapeutic target for chemoprevention and cancer therapy [143, 144]. However, recent studies have reported that the effects of TZDs on cell growth do not require the presence of PPARγ [145–147]. Furthermore, PPAR agonists appear to promote tumorigenesis in multiple rodent species and in both sexes [148], suggesting that TZDs may increase the risk of cancer or promote cancer progression in humans.

5.3. Insulin Secretagogues, Insulin, and Insulin Analogos. Secretagogues bind to specific cell receptors on β-cells, leading to depolarization of the plasma membrane and release of insulin stores. This class of drugs includes sulfonylureas and rapid-acting glinides. Results of observational studies indicate that secretagogues increase the risk of HCC in patients with DM [112, 116, 121, 122, 134]. Hassan et al. found that sulfonylurea use increased the risk of HCC in diabetic patients by 7-fold (adjusted OR, 7.1; 95% CI, 2.9–16.9) [134]. Bosetti et al. reported a higher risk for repaglinide (OR, 2.12; 95% CI, 1.38–3.26) than for sulfonylureas (OR, 1.39; 95% CI 0.98–1.99) [122]. However, in most of these studies, few of the diabetic patients using sulfonylureas developed cancer [149, 150].

Many patients with DM eventually require insulin as β-cell function decreases; therefore, insulin is used more often by patients with longer duration of DM and those with more complications [133, 151, 152]. Yu et al. reported a higher risk of HCC in patients with T2DM treated with insulin (RR, 18.5; 95% CI, 2.2–156.0) [108], and a meta-analysis performed by Singh et al. reported a 161% increased risk of HCC in patients treated with insulin [121]. Bosetti et al. reported that the risk of HCC was further increased with prolonged insulin use [122]. However, studies by Miele et al. did not find a significantly higher risk of HCC in patients receiving insulin [134, 153].

Both insulin and insulin secretagogues upregulate IGF-1 activity, which increases hepatic cell proliferation and alters cell metabolism [40, 154, 155]. In addition, these drugs can cause hyperinsulinemia, hepatotoxicity, and weight gain [156], indicating that their use in patients with chronic liver disease may increase the risk of HCC [157]. Future studies comparing the effects of antidiabetic medications on HCC...
risk should consider the severity of DM, because insulin is often prescribed in DM that is more severe or of longer duration.

6. Duration of DM and HCC Development

The duration of DM prior to HCC development may play an important role in the relationship between DM and HCC. A case-control study in Canada showed that the risk of HCC was higher in individuals with a longer history of DM [28]. Similarly, a meta-analysis by Wang et al. indicated that those with a history of DM > 10 years had the highest risk of HCC; however, this study had relatively low power because of the small number of studies included [158]. Hassan et al. reported that, compared with patients with a DM duration of 2–5 years, the risk of HCC was higher in those with a DM duration of 6–10 years (adjusted OR, 1.8; 95% CI, 0.8–4.1) or > 10 years (adjusted OR, 2.2; 95% CI, 1.2–4.8) [134]. Miele et al. also found a higher risk of HCC with longer duration of DM (OR, 2.96 for <10 years; OR, 5.33 for >10 years) [153]. Several other studies also observed that longer duration of DM was associated with an increased risk of HCC [64, 108, 138, 159–161]. In contrast, Wang et al. found that the risk of HCC among patients with a duration of DM < 5 years was higher than that of patients with duration of 5–10 years (RR, 3.76 versus 3.17) [159]; however, this difference was not significant. In our previous study, results of multivariate analysis showed that longer duration of DM (>5 years) did not significantly increase HCC risk [71].

Taken together, most of studies which investigated positively relationship between DM duration and HCC risk suggest that duration of DM > 10 years increases the risk of HCC; however, larger studies are needed to confirm these results. Meanwhile, the severity of DM should be clarified because patients with longer duration are likely to have more severe DM which might impact HCC development.

7. Conclusion

Diabetes mellitus is globally endemic, and increasing evidence from observational studies suggests that DM is a risk factor for HCC. Therefore, the increasing prevalence of DM may increase the incidence of HCC. The use of metformin, first-line therapy for DM, is associated with a decreased incidence of HCC, whereas insulin, generally used by patients with longer duration of DM or more complications, is associated with an increased incidence of HCC. Further research is needed to determine whether these relationships are causal or influenced by the duration or severity of DM and whether the results were affected by residual bias or misclassification.

In addition, studies are needed to elucidate the possible effects of antidiabetic drug type/dosage and duration of DM on the risk of HCC and to better understand the relationship between DM and HCC with different etiologies.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] S. H. Mehta, F. L. Brancati, S. A. Strathdee et al., "Hepatitis C virus infection and incident type 2 diabetes," *Hepatology*, vol. 38, no. 1, pp. 50–56, 2003.
[2] A. A. Butt, U. A. Khan, K. A. McGinnis, M. Skanderson, and C. Kent Kwoh, "Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans," *Journal of Viral Hepatitis*, vol. 14, pp. 890–896, 2007.
[3] F. Imazeki, O. Yokosuka, K. Fukai, T. Kanda, H. Kojima, and H. Saisho, "Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients," *Liver International*, vol. 28, no. 3, pp. 355–362, 2008.
[4] D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, "IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030," *Diabetes Research and Clinical Practice*, vol. 94, pp. 311–321, 2011.
[5] L. Guariguata, D. Whiting, I. Hambleton, J. Beagley, U. Linnenkamp, and J. Shaw, "Global estimates of diabetes prevalence for 2013 and projections for 2035," *Diabetes Research and Clinical Practice*, vol. 103, no. 2, pp. 137–149, 2014.
[6] N. Sudharsanan, M. K. Ali, N. K. Mehta, and K. M. Narayan, "Population aging, macroeconomic changes, and global diabetes prevalence, 1990-2008," *Population health metrics*, vol. 13, article 33, 2015.
[7] S. Leahy, A. M. O’Halloran, N. O’Leary et al., "Prevalence and correlates of diagnosed and undiagnosed type 2 diabetes mellitus and pre-diabetes in older adults: Findings from the Irish Longitudinal Study on Ageing (TILDA)," *Diabetes Research and Clinical Practice*, vol. 110, no. 3, pp. 241–249, 2015.
[8] H. King, R. E. Aubert, and W. H. Herman, "Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections," *Diabetes Care*, vol. 21, no. 9, pp. 1414–1431, 1998.
[9] S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030," *Diabetes Care*, vol. 27, no. 5, pp. 1047–1053, 2004.
[10] J. E. Shaw, R. A. Sicree, and P. Z. Zimet, "Global estimates of the prevalence of diabetes for 2010 and 2030," *Diabetes research and clinical practice*, vol. 87, pp. 4–14, 2010.
[11] D. H. Lawson, J. M. Gray, C. McKillop, J. Clarke, F. D. Lee, and R. S. Patrick, "Diabetes mellitus and primary hepatocellular carcinoma," *QJM: An International Journal of Medicine*, vol. 61, no. 1, pp. 945–955, 1986.
[12] M. M. Hassan, A. Frome, Y. Z. Patt, and H. B. El-Serag, "Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States," *Journal of Clinical Gastroenterology*, vol. 35, no. 3, pp. 266–269, 2002.
[13] J. M. Yuan, S. Govindarajan, K. Arakawa, and M. C. Yu, "Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.," *Cancer*, vol. 101, pp. 1009–1017, 2004.
[14] J. A. Davila, R. O. Morgan, Y. Shaib, K. A. McGlynn, and H. B. El-Serag, "Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study," *Gut*, vol. 54, pp. 533–539, 2005.
[15] E. Giovannucci, D. M. Harlan, M. C. Archer et al., "Diabetes and cancer: a consensus report," *Diabetes Care*, vol. 33, no. 7, pp. 1674–1685, 2010.
[16] A. Mantovani and G. Targher, "Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty
liver disease,” *Annals of translational medicine*, vol. 5, article 270, 2017.

[17] A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis,” *Cancer Prevention Research*, vol. 3, no. 11, pp. 1451–1461, 2010.

[18] K. Fujita, H. Iwama, H. Miyoshi et al., “Diabetes mellitus and metformin in hepatocellular carcinoma,” *World Journal of Gastroenterology*, vol. 22, no. 27, pp. 6100–6113, 2016.

[19] A. Marble, “Diabetes and cancer,” *The New England Journal of Medicine*, vol. 311, no. 8, pp. 339–349, 1993.

[20] H. O. Adami, J. McLaughlin, A. Ekbom et al., “Cancer risk in patients with diabetes mellitus,” *Cancer Causes & Control: CCC*, vol. 2, pp. 307–314, 1991.

[21] H.-O. Adami, W.-H. Chow, O. Nyren et al., “Excess risk of primary liver cancer in patients with diabetes mellitus,” *Journal of the National Cancer Institute*, vol. 88, no. 20, pp. 1472–1477, 1996.

[22] L. Wideroff, G. Gridley, L. Mellemkjaer et al., “Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in denmark,” *Journal of the National Cancer Institute*, vol. 89, no. 18, pp. 1360–1365, 1997.

[23] M. S. Lai, M. S. Hsieh, Y. H. Chiu, and T. H. Chen, “Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection,” *Hepatology*, vol. 43, pp. 1295–1302, 2006.

[24] C. Chen, H. Yang, W. Yang et al., “Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan,” *Gastroenterology*, vol. 135, no. 1, pp. 111–121, 2008.

[25] C. La Vecchia, E. Negri, S. Franceschi, B. D’Avanzo, and P. Boyle, “A case-control study of diabetes mellitus and cancer risk,” *British Journal of Cancer*, vol. 70, no. 5, pp. 950–953, 1994.

[26] H. B. El-Serag, H. Hampel, and F. Javadi, “The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence,” *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of The American Gastroenterological Association*, vol. 4, pp. 369–380, 2006.

[27] K. Tanaka, I. Tsuji, A. Tamakoshi et al., “Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population,” *Japanese Journal of Clinical Oncology*, vol. 44, no. 10, pp. 986–999, 2014.

[28] M. C. Rousseau, M. E. Parent, M. N. Pollak, and J. Siemiatycki, “Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada,” *International Journal of Cancer*, vol. 118, pp. 2105–2109, 2006.

[29] J. Polesel, A. Zuccchetto, M. Montella et al., “The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma,” *Annals of Oncology*, vol. 20, no. 2, pp. 353–357, 2009.

[30] C.-T. Chen, J.-Y. Chen, J.-H. Wang et al., “Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan,” *Kaohsiung Journal of Medical Sciences*, vol. 29, no. 8, pp. 451–459, 2013.

[31] S. N. Lu, T. M. Lin, C. J. Chen et al., “A case-control study of primary hepatocellular carcinoma in Taiwan,” *Cancer*, vol. 62, no. 9, pp. 2051–2055, 1988.

[32] H. B. El-Serag, P. A. Richardson, and J. E. Everhart, “The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans,” *The American journal of gastroenterology*, vol. 96, pp. 2462–2467, 2001.

[33] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” *Diabetes Care*, vol. 27, supplement 1, pp. S5–S10, 2004.

[34] C. K. Chou, L. T. Ho, L. P. Ting et al., “Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin.” *The Journal of Clinical Investigation*, vol. 79, no. 1, pp. 175–178, 1987.

[35] D. Ish-Shalom, C. T. Christoffersen, P. Vorwerk et al., “Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor,” *Diabetologia*, vol. 40, no. 2, pp. S25–S31, 1997.

[36] E. S. Ford and M. E. Cogswell, “Diabetes and serum ferritin concentration among U.S. adults,” *Diabetes Care*, vol. 22, no. 12, pp. 1978–1983, 1999.

[37] L. J. Niederhofer, J. S. Daniels, C. A. Rouzer, R. E. Greene, and L. J. Marnett, “Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells,” *The Journal of Biological Chemistry*, vol. 278, pp. 31426–31433, 2003.

[38] R. G. Rosenfeld, “Insulin-like Growth Factors and the Basis of Growth,” *The New England Journal of Medicine*, vol. 349, no. 23, pp. 2184–2186, 2003.

[39] E. E. Calle and R. Kaaks, “Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms,” *Nature Reviews. Cancer*, vol. 4, pp. 579–591, 2004.

[40] S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson, “Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider,” *Diabetes Care*, vol. 29, pp. 1990–1991, 2006.

[41] M. A. Moore, C. B. Park, and H. Tuda, “Implications of the hyperinsulinemia-diabetes-cancer link for preventive efforts,” *European Journal of Cancer Prevention: The Official Journal of The European Cancer Prevention Organisation (ECP)*, vol. 7, pp. 89–107, 1998.

[42] V. Paradis, G. Perlemuter, F. Bonvoust et al., “High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis,” *Hepatology*, vol. 34, no. 4 L, pp. 738–744, 2001.

[43] D. G. Fong, V. Nehra, K. D. Lindor, and A. L. Buchman, “Metabolic and nutritional considerations in nonalcoholic fatty liver,” *Hepatology*, vol. 32, pp. 3–10, 2000.

[44] S. Zaman, R. Johnson, P. Johnson, W. Melia, B. Portmann, and R. Williams, “Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients,” *The Lancet*, vol. 1, pp. 1357–1360, 1985.

[45] O. Warburg, “Aerobic respiration and fermentation,” *Science*, vol. 123, no. 3191, pp. 309–314, 1956.

[46] M. Kar and A. S. Chakraborti, “Release of iron from haemoglobin—a possible source of free radicals in diabetes mellitus,” *Indian Journal of Experimental Biology*, vol. 37, pp. 190–192, 1999.

[47] M. M. Hassan, L.-Y. Hwang, and C. J. Hatten, “Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus,” *Hepatology*, vol. 36, no. 5, pp. 1206–1213, 2002.
[49] F. Donato, A. Tagger, U. Gelatti et al., "Alcohol and hepatocellular virus infections in men and women," American Journal of Epidemiology, vol. 155, no. 4, pp. 323–331, 2002.

[50] M. M. Ali Kamkar, R. Ahmad, O. Alsamadi, and K. Behbehani, "Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review," Journal of diabetes and metabolic disorders, vol. 13, article 57, 2014.

[51] A. Pfeiffer, C. Drewes, K. Middelberg-Bisping, and H. Schatz, "Elevated plasma levels of transforming growth factor-β1 in NIDDM," Diabetes Care, vol. 19, no. 10, pp. 1113–1117, 1996.

[52] J. P. Bastard, C. Jardel, E. Bruckert et al., "Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss," The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 9, pp. 3338–3342, 2000.

[53] H. E. Thomas, W. Irawaty, R. Darwiche et al., "IL-1 receptor deficiency slows progression to diabetes in the NOD mouse," Diabetes, vol. 53, no. 1, pp. 113–121, 2004.

[54] J. N. Fain, "Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: A review," Mediators of Inflammation, vol. 2010, Article ID 513948, 2010.

[55] R. Goyal, A. F. Faizy, S. S. Siddiqui, and M. Singhai, "Evaluation of TNF-alpha and IL-6 levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects," of TNF-alpha and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects," International Journal of Endocrinology & Metabolism, vol. 4, pp. 180–184, 2012.

[56] H. Nakagawa, S. Maeda, H. Yoshida et al., "Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences," Endocrinology & Metabolism, vol. 125, no. 10, pp. 2264–2269, 2009.

[57] V. W.-S. Wong, J. Yu, A. S.-L. Cheng et al., "High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B," International Journal of Cancer, vol. 124, no. 12, pp. 2766–2770, 2009.

[58] E. J. Park, J. H. Lee, G.-Y. Yu et al., "Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression," Cell, vol. 140, no. 2, pp. 197–208, 2010.

[59] S. K. Garg, H. Maurer, K. Reed, and R. Selagamsetty, "Diabetes and cancer: two diseases with obesity as a common risk factor," Diabetes, Obesity & Metabolism, vol. 16, pp. 97–110, 2014.

[60] F. Hong, W.-H. Kim, Z. Tian et al., "Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytotoxic agent against ethanol-induced apoptosis in the liver: Involvement of induction of bcl-2 and bcl-xl proteins," Oncogene, vol. 21, no. 1, pp. 32–43, 2002.

[61] B. B. Aggarwal, A. B. Kunnunmakkara, K. B. Harikumar et al., "Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?" Annals of the New York Academy of Sciences, vol. 1171, pp. 59–76, 2009.

[62] X. Zhang, S. Tachibana, H. Wang et al., "Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice," Hepatology, vol. 52, no. 6, pp. 2137–2147, 2010.

[63] F. Turati, R. Talamini, C. Pelucchi et al., "Metabolic syndrome and hepatocellular carcinoma risk," British Journal of Cancer, vol. 108, no. 1, pp. 222–228, 2013.

[64] H. B. El-Serag, T. Tran, and J. E. Everhart, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma," Gastroenterology, vol. 126, no. 2, pp. 460–468, 2004.

[65] Y. Fujino, T. Mizoue, N. Tokui, and T. Yoshimura, "Prospective study of diabetes mellitus and liver cancer in Japan," Diabetes/Metabolism Research and Reviews, vol. 17, no. 5, pp. 374–379, 2001.

[66] L. Yu, D. A. Sloane, C. Guo, and C. D. Howell, "Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000," Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of The American Gastroenterological Association, vol. 4, pp. 355–360, 2006.

[67] J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. F. Hutin, and B. P. Bell, "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide," Journal of Hepatology, vol. 45, no. 4, pp. 529–538, 2006.

[68] Y.-G. Wang, P. Wang, B. Wang, Z.-J. Fu, W.-J. Zhao, and S.-L. Yan, "Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis," PLoS ONE, vol. 9, no. 5, Article ID e95485, 2014.

[69] H. K. Dyal, M. Aguilar, G. Bartos et al., "Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review," Digestive Diseases and Sciences, vol. 61, no. 2, pp. 636–645, 2016.

[70] T. Huang, C. Lin, M. Lu et al., "Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study," Journal of Gastroenterology and Hepatology, vol. 32, no. 7, pp. 1355–1362, 2016.

[71] X. Li, H. Xu, Y. Gao, M. Pan, L. Wang, and P. Gao, "Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China," Medicine, vol. 96, no. 13, e6508, 2017.

[72] B. J. Veldt, W. Chen, E. J. Heathcote et al., "Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus," Hepatology, vol. 47, no. 6, pp. 1856–1862, 2008.

[73] C. Gao and S. K. Yao, "Diabetes mellitus: a “true” independent risk factor for hepatocellular carcinoma?" Hepatobiliary & pancreatic diseases international : HBPD INT, vol. 8, pp. 465–473, 2009.

[74] D. Kumar, G. C. Farrell, C. Fung, and J. George, "Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response," Hepatology, vol. 36, pp. 1266–1272, 2002.

[75] T. Poynard, F. Imbert-Bismut, V. Ratziu et al., "Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial," Journal of Viral Hepatitis, vol. 9, no. 2, pp. 128–133, 2002.

[76] C. Dai, J. Huang, M. Hsieh et al., "Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients," Journal of Hepatology, vol. 50, no. 4, pp. 712–718, 2009.

[77] D. Kraäl, L. V. Jukić, S. Stojasavljevic, M. Duvnjak, M. Smolic, and I. B. Curcic, "Hepatitis C virus, insulin resistance, and steatosis," Journal of Clinical and Translational Hepatology, vol. 4, no. 1, pp. 66–75, 2016.

[78] F. X. Bosch, J. Ribes, M. Diaz, and R. Cleries, "Primary liver cancer: worldwide incidence and trends," Gastroenterology, vol. 127, pp. s5–s16, 2004.

[79] J. Bruix and M. Sherman, "Management of hepatocellular carcinoma: an update," Hepatology, vol. 53, pp. 1020–1022, 2011.

[80] J. Ho, P. C. Wu, and T. M. Kung, "An autopsy study of hepatocellular carcinoma in Hong Kong," Pathology, vol. 13, pp. 409–416, 1981.
[81] A. S.-F. Lok, C.-L. Lai, P.-C. Wu, V.-C. Wong, E.-K. Yeoh, and H.-J. Lin, “Hepatitis b virus infection in chinese families in Hong Kong,” American Journal of Epidemiology, vol. 126, no. 3, pp. 492–499, 1987.

[82] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 96–99, 2011.

[83] C. Gao, L. Fang, H. C. Zhao, J. T. Li, and S. K. Yao, “Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection,” Hepatology & Pancreatic Diseases International : HBPD INT, vol. 12, pp. 385–393, 2013.

[84] J. C. Hsiang, E. J. Gane, W. W. Bai, and S. J. Gerred, “Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients,” Journal of Gastroenterology and Hepatology, vol. 30, pp. 591–599, 2015.

[85] K. Amano, T. Kawaguchi, R. Kuromatsu et al., “Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012,” Molecular and Clinical Oncology, 2014.

[86] W. H. Ko, S. Y. Chiu, K. C. Yang, and H. H. Chen, “Diabetes, hepatitis virus infection and hepatocellular carcinoma: a case-control study in hepatitis endemic area,” Hepatology Research : The Official Journal of The Japan Society of Hepatology, vol. 42, pp. 774–781, 2012.

[87] S. C. Fu, Y. W. Huang, T. C. Wang, J. T. Hu, D. S. Chen, and S. S. Yang, “Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study,” Alimentary Pharmacology & Therapeutics, vol. 41, pp. 1200–1209, 2015.

[88] H. Han, H. Deng, T. Han, H. Zhao, F. Hou, and X. Qi, “Association between hepatocellular carcinoma and type 2 diabetes mellitus in Chinese hepatitis B virus cirrhosis patients: a case-control study,” Medical Science Monitor, vol. 23, pp. 3324–3334, 2017.

[89] C. Chiang, H. Yang, C. Jen et al., “Association between obesity, hypertriglyceridemia and low hepatitis B viral load,” International Journal of Obesity, vol. 37, no. 3, pp. 410–415, 2013.

[90] S. Mittal and H. B. El-Serag, “Epidemiology of hepatocellular carcinoma: consider the population,” Journal of Clinical Gastroenterology, 47, pp. S2–S6, 2013.

[91] F. Z. Khan, R. B. Perumpail, R. J. Wong, and A. Ahmed, “Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma,” World Journal of Hepatology, vol. 7, no. 18, pp. 2155–2161, 2015.

[92] E. E. Powell, W. G. E. Cooksey, and R. Hanson, “The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years,” Hepatology, vol. 11, no. 1, pp. 74–80, 1990.

[93] P. L. Jansen, “Non-alcoholic steatohepatitis,” European Journal of Gastroenterology & Hepatology, vol. 16, pp. 1079–1085, 2004.

[94] L. A. Adams, J. F. Lymph, J. St. Sauver et al., “The natural history of nonalcoholic fatty liver disease: a population-based cohort study,” Gastroenterology, vol. 129, no. 1, pp. 113–121, 2005.

[95] Y. Nagaoki, H. Hyogo, H. Ai kata et al., “Recent trend of clinical features in patients with hepatocellular carcinoma,” H epatology Research, vol. 42, no. 4, pp. 368–375, 2012.

[96] O. S. Kwon, J. H. Kim, and J. H. Kim, “The development of hepatocellular carcinoma in non-alcoholic fatty liver disease,” The Korean Journal of Gastroenterology = Tae han Sohwagi H akhoe Chi, vol. 69, pp. 348–352, 2017.

[97] K. Tokushige, E. Hashimoto, Y. Horie, M. Tanai, and S. Higuchi, “Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey,” Journal of Gastroenterology, vol. 51, no. 6, pp. 586–596, 2016.

[98] G. Cholankeril, R. Patel, S. Khurana, and S. K. Satapathy, “Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management,” World Journal of Hepatology, vol. 9, pp. 533–543, 2017.

[99] A. Gastañedella, “Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?” Clinical Science, vol. 131, no. 22, pp. 2701–2704, 2017.

[100] M. Montella, A. Crispo, and A. Giudice, “HCC, diet and metabolic factors: diet and HCC,” Hepatitis Monthly, vol. 11, no. 3, pp. 159–162, 2011.

[101] H. Chetouh, M. Lequoy, L. Dartoux, C. Vigouroux, and C. Desbois-Mouthon, “Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma,” Liver International, vol. 35, no. 10, pp. 2203–2217, 2015.

[102] M. Ueyama, N. Nishida, M. Korenaga et al., “The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus,” Journal of Gastroenterology, vol. 51, no. 4, pp. 370–379, 2016.

[103] K. Oda, H. Uto, S. Mawatari, and A. Ido, “Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies,” Clinical Journal of Gastroenterology, vol. 8, pp. 1–9, 2015.

[104] M. Kikuchi, Y. Horie, H. Ebimuna, N. Taniki, N. Nakamoto, and T. Kanai, “Alcoholic Liver Cirrhosis and Significant Risk Factors for the Development of Alcohol-related Hepatocellular Carcinoma–Japan;” Nihon Arukoru Yakubutsu Igakukai Zassi = Japanese journal of alcohol studies drug dependence, pp. 222–234, 2012.

[105] E. J. Raff, D. Kakati, I. R. Bloomer, M. Shoreibah, K. Rasheed, and A. K. Singal, “Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases,” Journal of Clinical and Translational Hepatology, vol. 3, no. 1, pp. 9–16, 2015.

[106] H. Völzke, “Multicausality in fatty liver disease: Is there a rationale to distinguish between alcoholic and non-alcoholic origin?” World Journal of Gastroenterology, vol. 18, no. 27, pp. 3492–3501, 2012.

[107] B. Raynard, A. Balian, D. Fallik et al., “Risk factors of fibrosis in alcohol-induced liver disease,” Hepatology, vol. 35, no. 3, pp. 635–638, 2002.

[108] M. C. Yu, B. E. Henderson, M. J. Tong, and S. Govindarajan, “Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-asians of los angeles county, California,” Journal of the National Cancer Institute, vol. 83, no. 24, pp. 1820–1826, 1991.

[109] C. La Vecchia, E. Negri, A. Decarli, and S. Franceschi, “Diabetes mellitus and the risk of primary liver cancer,” International Journal of Cancer, vol. 73, no. 2, pp. 204–207, 1997.

[110] H. Noto, A. Goto, T. Tsujimoto, and M. Noda, “Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis,” PLoS One, vol. 7, Article ID e33411, 2012.

[111] D. Soranna, L. Scotti, A. Zambon et al., “Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis,” The Oncologist, vol. 17, no. 6, pp. 813–822, 2012.

[112] C.-H. Chang, J.-W. Lin, L.-C. Wu, M.-S. Lai, L.-M. Chuang, and K. Arnold Chan, “Association of thiazolidinediones with...
liver cancer and colorectal cancer in type 2 diabetes mellitus," *Hepatology*, vol. 55, no. 5, pp. 1462–1472, 2012.

[113] J. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, "Metformin and reduced risk of cancer in diabetic patients," BMJ, vol. 330, pp. 1304–1305, 2005.

[114] C. H. Chang, J. W. Lin, L. C. Wu, M. S. Lai, and L. M. Chuang, "Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus," *The Journal of Clinical Endocrinology and Metabolism*, vol. 97, pp. E1170–E1175, 2012.

[115] D. M. Nathan, J. B. Buse, M. B. Davidson et al., "Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes," *Diabetologia*, vol. 52, pp. 17–30, 2009.

[116] V. Donadon, M. Babli, M. Ghersetti et al., "Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease," *World Journal of Gastroenterology*, vol. 15, no. 20, pp. 2506–2511, 2009.

[117] V. Donadon, M. Babli, F. Valenti, and A. Avogaro, "Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma," *World Journal of Gastroenterology*, vol. 16, no. 24, pp. 3025–3032, 2010.

[118] M.-S. Lee, C.-C. Hsu, M. L. Wahlqvist, H.-N. Tsai, Y.-H. Chang, and Y.-C. Huang, "Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals," *BMJ Cancer*, vol. 11, article 20, 2011.

[119] Z.-J. Zhang, Z.-J. Zheng, R. Shi, Q. Su, Q. Jiang, and K. E. Kip, "Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis," *The Journal of Clinical Endocrinology & Metabolism*, vol. 97, no. 7, pp. 2347–2353, 2012.

[120] H.-P. Chen, J.-J. Shieh, C.-C. Chang et al., "Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies," *Gut*, vol. 62, no. 4, pp. 606–615, 2013.

[121] S. Singh, P. P. Singh, A. G. Singh, M. H. Murad, and W. Sanchez, "Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis," *The American Journal of Gastroenterology*, vol. 108, pp. 881–891, 2013.

[122] C. Bosetti, M. Franchi, F. Nicorota et al., "Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases," *Pharmacoepidemiology and Drug Safety*, vol. 24, no. 7, pp. 771–778, 2015.

[123] D. K. DePeralta, L. Wei, S. Ghoshal et al., "Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis," *Cancer*, vol. 122, no. 8, pp. 1216–1227, 2016.

[124] K. K. Tsilidis, D. Capothanassi, N. E. Allen et al., "Metformin does not affect cancer risk: A cohort study in the U.K. clinical practice research datalink analyzed like an intervention-to-treat trial," *Diabetes Care*, vol. 37, no. 9, pp. 2522–2532, 2014.

[125] B. Thakkar, K. N. Aronis, M. T. Vanvini, K. Shields, and C. S. Mantzoros, "Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies," *Metabolism - Clinical and Experimental*, vol. 62, no. 7, pp. 922–934, 2013.

[126] R. J. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg, "Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells," *Cancer Research*, vol. 67, pp. 10804–10812, 2007.

[127] E. J. Gallagher and D. LeRoith, "Diabetes, cancer, and metformin: connections of metabolism and cell proliferation," *Annals of the New York Academy of Sciences*, vol. 1243, pp. 54–68, 2011.

[128] H. Z. Lin, S. Q. Yang, C. Chuckaree, F. Kuhajda, G. Ronnet, and A. M. Diehl, "Metformin reverses fatty liver disease in obese, leptin-deficient mice," *Nature Medicine*, vol. 6, no. 9, pp. 998–1003, 2000.

[129] G. Marchesini, M. Brizi, G. Bianchi, S. Tommasetti, M. Zoli, and N. Melchionda, "Metformin in non-alcoholic steatohepatitis," *The Lancet*, vol. 358, no. 9285, pp. 893–894, 2001.

[130] S. Nair, A. M. Diehl, M. Wiseman, G. H. Farr, and R. P. Perrillo, "Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial," *Alimentary Pharmacology & Therapeutics*, vol. 20, pp. 23–28, 2004.

[131] A. Uygun, A. Kadayifci, A. T. Isik et al., "Metformin in the treatment of patients with non-alcoholic steatohepatitis," *Alimentary Pharmacology & Therapeutics*, vol. 19, pp. 537–544, 2004.

[132] J. W. Haukeland, Z. Konopski, H. B. Eggsho et al., "Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial," *Scandinavian Journal of Gastroenterology*, vol. 44, no. 7, pp. 853–860, 2009.

[133] E. Giovannucci, D. M. Harlan, and M. C. Archer, "Diabetes and cancer: a consensus report," *CA: A Cancer Journal for Clinicians*, vol. 60, no. 4, pp. 207–221, 2010.

[134] M. M. Hassan, S. A. Curley, D. Li et al., "Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma," *Cancer*, vol. 116, no. 8, pp. 1938–1946, 2010.

[135] S.-W. Lai, P.-C. Chen, K.-F. Liao, C.-H. Muo, C.-C. Lin, and F.-C. Sung, "Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study," *American Journal of Gastroenterology*, vol. 107, no. 1, pp. 46–52, 2012.

[136] C.-C. Chiu, C.-C. Huang, Y.-C. Chen et al., "Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with Anti-Diabetes drugs: A nationwide population-based study in Taiwan," *Internal Medicine*, vol. 52, no. 9, pp. 939–946, 2013.

[137] C. Bosetti, V. Rosato, D. Buniato, A. Zambon, C. La Vecchia, and G. Corrao, "Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis," *The Oncologist*, vol. 18, no. 2, pp. 148–156, 2013.

[138] S. Schlesinger, K. Aleksandrova, T. Pischon et al., "Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European population-based cohort study," *Annals of Oncology*, vol. 24, no. 9, pp. 2449–2455, 2013.

[139] S. A. Oliveria, C. E. Koro, M. U. Vood, and M. Sowell, "Cancer incidence among patients treated with antidiabetic phar- macotherapy," *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, vol. 2, no. 1, pp. 47–57, 2008.

[140] T. Kawaguchi, E. Taniguchi, Y. Morita et al., "Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection," *Liver International*, vol. 30, no. 3, pp. 479–486, 2010.

[141] K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, "Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid..."
carcinoma cells,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 86, pp. 2170–2177, 2001.

[142] T. Okumura, “Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs,” *Journal of Gastroenterology*, vol. 45, no. 11, pp. 1097–1102, 2010.

[143] D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, “PPARgamma as a therapeutic target for tumor angiogenesis and metastasis,” *Cancer Biology & Therapy*, vol. 4, pp. 687–693, 2005.

[144] F. Ondrey, “Peroxisome proliferator-activated receptor γ pathway targeting in carcinogenesis: implications For Chemoprevention,” *Clinical Cancer Research*, vol. 15, no. 1, pp. 2–8, 2009.

[145] C. E. Clay, A. M. Namen, G. Atsumi et al., “Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells,” *Journal of Investigative Medicine*, vol. 49, no. 5, pp. 413–420, 2001.

[146] S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, “Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation,” *Cancer Research*, vol. 61, no. 16, pp. 6213–6218, 2001.

[147] C. E. Clay, A. Monjazeb, J. Thorburn, F. H. Chilton, and K. P. High, “15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells,” *Journal of Lipid Research*, vol. 43, no. 11, pp. 1818–1828, 2002.

[148] A. Rubenstrunk, R. Hanf, D. W. Hum, J. C. Fruchart, and B. Staels, “Safety issues and prospects for future generations of PPAR modulators,” *Biochimica Et Biophysica Acta*, vol. 1771, pp. 1065–1081, 2007.

[149] C. J. Currie, “The longest ever randomised controlled trial of insulin glargine: Study design and HbA1c findings,” *Diabetologia*, vol. 52, no. 10, pp. 2234-2235, 2009.

[150] C. J. Currie, C. D. Poole, and E. A. Gale, “The influence of glucose-lowering therapies on cancer risk in type 2 diabetes,” *Diabetologia*, vol. 52, pp. 1766–1777, 2009.

[151] S. Inchiostro, G. Bertoli, G. Zanette et al., “Increased urinary albumin excretion is associated with a cluster of metabolic alterations in type 2 diabetes mellitus,” *Acta Diabetologica*, vol. 29, no. 3-4, pp. 240–245, 1992.

[152] S. Inchiostro, G. Bertoli, G. Zanette, and V. Donadon, “Evidence of higher insulin resistance in NIDDM patients with ischaemic heart disease,” *Diabetologia*, vol. 37, no. 6, pp. 597–603, 1994.

[153] L. Miele, C. Bosetti, and F. Turati, “Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk,” *Gastroenterology Research and Practice*, vol. 2015, Article ID 570356, 2015.

[154] C. La Vecchia, “Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk,” *Metabolism - Clinical and Experimental*, vol. 60, no. 10, pp. 1357-1358, 2011.

[155] G. Pasello, L. Urso, P. Conte, and A. Favaretto, “Effects of sulfonylureas on tumor growth: a review of the literature,” *The Oncologist*, vol. 18, pp. 1118–1125, 2013.

[156] R. A. DeFronzo, “Pharmacologic therapy for type 2 diabetes mellitus,” *Annals of Internal Medicine*, vol. 131, no. 4, pp. 281–303, 1999.

[157] K. Aston-Mourney, J. Proietto, G. Morahan, and S. Andrikopoulos, “Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin,” *Diabetologia*, vol. 51, no. 4, pp. 540–545, 2008.

[158] P. Wang, D. Kang, W. Cao, Y. Wang, and Z. Liu, “Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis,” *Diabetes/Metabolism Research and Reviews*, vol. 28, pp. 109–122, 2012.

[159] C. Wang, X. Wang, G. Gong et al., “Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies,” *International Journal of Cancer*, vol. 130, no. 7, pp. 1639–1648, 2012.

[160] G. Y. Lai, Y. Park, P. Hartge, A. R. Hollenbeck, and N. D. Freedman, “The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 98, pp. E497–E502, 2013.

[161] T. G. Simon, L. Y. King, D. Q. Chong et al., “Diabetes, metabolic comorbidities and risk of hepatocellular carcinoma: results from two prospective cohort studies,” *Hepatology*, 2017.